feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / New TB Vaccine Promises Hope Against Deadly Disease

New TB Vaccine Promises Hope Against Deadly Disease

25 Nov, 2025

•

Summary

  • A new HSP Subunit Vaccine is nearing commercial availability.
  • Existing vaccines are largely ineffective for adult TB prevention.
  • IIT Bhubaneswar and ILS Bhubaneswar developed the novel vaccine.
New TB Vaccine Promises Hope Against Deadly Disease

A new generation HSP Subunit Vaccine, designed to combat Mycobacterium tuberculosis, is approaching commercial availability. Developed through collaborative research between the Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS) Bhubaneswar, this vaccine addresses the critical gap in preventing pulmonary tuberculosis in adolescents and adults.

The existing Bacillus Calmette Guérin (BCG) vaccine, over a century old, provides only limited protection to infants and is largely ineffective in older age groups. Tuberculosis remains a significant global health threat, with the WHO reporting 1.23 million deaths in 2024 alone, underscoring the urgent need for improved prevention strategies.

TechInvention Lifecare Limited has entered into a license agreement for the technology transfer and commercialization of this novel vaccine. This partnership aims to efficiently translate the indigenous vaccine technology from research to product development and eventual market availability, marking a significant step forward in India's efforts to control the TB epidemic.

trending

Islamabad suicide blast kills 31

trending

Ronaldo trains with Al Nassr

trending

India A vs Namibia live

trending

Vaibhav Suryavanshi scores 175

trending

VTU adopts Artificial Super Intelligence

trending

Riyan Parag scores fifty

trending

T20 World Cup opening ceremony

trending

Tiigers Kolkata reach ISPL final

trending

Al Ettifaq favored vs Damac

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The new HSP Subunit Vaccine was jointly developed by IIT Bhubaneswar and the Institute of Life Sciences (ILS) Bhubaneswar.
The BCG vaccine is over a century old, offers limited protection to infants, and is largely ineffective against pulmonary TB in adolescents and adults.
The HSP Subunit Vaccine is expected to be commercially available soon following a licensing agreement.

Read more news on

Healthside-arrow

You may also like

Covid Jabs & Fertility: New Study Debunks Myth

1 day ago • 8 reads

article image

China Approves First Homegrown Subunit Flu Vaccine

2 Feb • 19 reads

article image

AAP Challenges CDC on Crucial Vaccine Guidance

27 Jan • 63 reads

UK Kids Unvaccinated: 1 in 5 Miss Deadly Disease Protection

1 Jan • 221 reads

article image

Indian Rabies Vaccine Linked to Counterfeit Scare

27 Dec, 2025 • 209 reads

article image